New Integrated Hematology Analyzer Launched

Currently, hematology testing requires a larger blood sample from a given patient, which needs to be run across several different systems in order to get the full set of results. This is labor- and time-intensive, and potentially provides inconsistent results, as slide images are difficult to interpret.

A new integrated hematology analyzer addresses the challenges of hematology testing by combining the three components of the process: a digital morphology analyzer, cell counter and classifier into one streamlined solution which prepares, stains and analyses microscopy blood slides.

The cobas m 511 provides greater accuracy and consistency of results, compared to current technologies, by identifying, counting, isolating and categorizing white blood cells, red blood cells and platelets, then presenting the digital images of all these cell types. Medical technologists can now concentrate their time on finding and classifying abnormal cells within patient samples. This automation and digitalization reduces the need for resource-intensive manual microscope reviews, supports clinicians to share challenging cases around the world and enables the delivery of quicker results, which ultimately aid patient diagnoses.

The cobas m 511, uses a unique approach to enter the new field of digital hematology through patented Bloodhound technology for printing, staining and imaging. This technology uses only 30µL of blood to print a monolayer onto the slide, stains with an improved method for further analysis of the morphology and enables classification of cells displayed on a Viewing Station. Based on these direct images, the Bloodhound technology counts, analyses morphology and then classifies every cell in the viewing area to provide a standard complete blood count (CBC) and 5-part differential and reticulocyte count.

The cobas m 511 integrated hematology analyzer, is now available for countries accepting the CE Mark. Roland Diggelmann, CEO of Roche Diagnostics, said, “With this launch, patients will benefit from a faster and more accurate diagnosis of blood diseases, as diverse as anemia and leukemia. We are entering a new area of innovation with Roche in hematology testing, supporting customers with integrated and efficient laboratory solutions, which deliver increased medical value.”